ResearchMoz

Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market

GBI Research
Published Date » 2013-01-04
No. Of Pages » 43
     
  Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market  
   
  Summary  
   
 Leading business intelligence provider GBI Research has released its latest research report, entitled “Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market”. The current opioids market is characterized by a very broad and highly diversified product portfolio. Patients experiencing moderate to severe pain for a range of underlying physiological reasons are virtually exclusively treated with opioid analgesics. As a result, most patient populations experiencing more severe levels of pain across most pain indications, with the...
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Introduction 7
2.1.1 High Levels of Product Diversification in a Highly Competitive Market Environment 7
2.1.2 Inconsistent Clinician Prescribing Preferences 7
2.1.3 Ongoing Market Shift Towards Abuse-Resistant Product Formulations 8
2.1.4 Increasingly Vocal Physician Associations Raise Concerns About Extent of Opioid Abuse 9
2.1.5 Full Commercial Potential of Transdermal Patches May Have Yet to be Fully Exploited 9

3 Overview of Currently Marketed Products 10
3.1 Major Marketed Products 10
3.1.1 Oxycontin 10
3.1.2 Exalgo 10
3.1.3 Onsolis 10
3.1.4 Duragesic 11
3.1.5 Opana ER 11
3.1.6 Vicodin CR 11
3.1.7 Dolophine Hydrochloride 11
3.1.8 Oxecta 11
3.1.9 Actiq 12
3.1.10 Embeda 12
3.1.11 Kadian 12
3.1.12 Avinza 12
3.2 Market Drivers and Barriers 13
3.2.1 Drivers 14
3.2.2 Barriers 15

4 Pipeline Analysis 17
4.1 Introduction 17
4.2 Opioid Compounds in the Developmental Pipeline 20
4.3 Distribution by Route of Administration 23
4.4 Promising Pipeline Products 26
4.4.1 ARX-01, AcelRX Pharmaceuticals 26
4.4.2 ALO-02, Pfizer 26
4.4.3 Zohydro ER, Zogenix 26
4.4.4 ELI-216, Elite Pharmaceuticals 27
4.4.5 BEMA Buprenorphine 27
4.4.6 CEP-33237, Cephalon 27

5 Deals Analysis 28
5.1 Overview: 28
5.1.1 M&As by Year 28
5.1.2 M&As by Value 29
5.1.3 Major M&As 30
5.2 Licensing Agreements 33
5.2.1 Licensing Agreements by Year 33
5.2.2 Licensing Agreements by Value 34
5.2.3 Major Licensing Agreements 35
5.3 Co-Development Agreements 38
5.3.1 Deals by Year 38
5.3.2 Major Co-Development Deals 39

6 Appendix 40
6.1 Abbreviations 40
6.2 Bibliography 41
6.3 Research Methodology 41
6.3.1 Coverage 41
6.3.2 Secondary Research 42
6.3.3 Primary Research 42
6.3.4 Pipeline Analysis 42
6.3.5 Expert Panel Validation 42
6.4 Contact Us 43
6.5 Disclaimer 43

List of Tables


Table 1: Opioids Market, Global, R&D Pipeline Analysis by Phase, 2012 18

List of Figures


Figure 1: Opioids Market, Drivers and Barriers, 2012 13
Figure 2: Opioids Market, Global, R&D Pipeline by Phase (%), 2012 17
Figure 3: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase III 20
Figure 4: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase II 21
Figure 5: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase I 22
Figure 6: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase III 23
Figure 7: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase II 24
Figure 8: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase I 25
Figure 9: Opioids Market, M&As by Year, 2005–2012 28
Figure 10: Opioids Market, M&As by Value ($m), 2005–2012 29
Figure 11: Opioids Market, Licensing Agreements by Year, 2005–2012 33
Figure 12: Opioids Market, Licensing Agreements by Value ($m), 2005–2012 34
Figure 13: Opioids Market, Co-Development Agreements by Year, 2005–2012 38

Upcoming Reports:

Machine To Machine Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
Machine to Machine also known as M2M, is a cumulating set of technologies which combines both wireless and wired network systems for communicating with other devices. The basic components of M2M systems are a sensory device which grabs signals and transmits them further to a network which could be both wireless as well as wired; an application software to process such data and finally into a relevant information. Certain major machine to machine technologies which are currently in vogue are 2G and 3G technologies, Wireless Fidelity (WiFi), Ethernet, ZigBee etc. Machine to...
Greece: womens blouses and shirts market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the womens blouses and shirts market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the womens blouses and shirts market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...
Energy Efficient Materials Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Increasing consumption of energy in buildings for various electrical appliances and peripherals has developed the idea of using energy efficient materials in building construction. Energy efficient materials are largely used for thermal insulation of buildings as a result of which, demand for these materials is on the rise. Thermal insulation is the most efficient and effective way to improve the energy utilization and efficiency in the building. This method will preserve the indoor heat during winter while keeping the building cool from inside in summers thus improving...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Order cancellations not a sign of market slump: Airbus
Jul 31, 2014  
Leading aircraft manufacturer Airbus on Wednesday said that the recent wave of order cancellations for its commercial jetliners do not mean that the market has declined. The market is still strong and single-aisle jets deals are likely to return later. A total of 225 Airbus cancellations were reported since the beginning of this year. Of these, Dubai’s Emirates Airlines alone...
Leading Australian Universities Want to Hike Fees, Enroll Fewer Students
Jul 31, 2014  
Australia’s prestigious group of top eight universities, also known as the Group of Eight (Go8), has indicated plans of increasing tuition fees while reducing the number of students they enroll, a reform-backer has predicted. These decisions could be made if the universities are deregulated .  Arguing for this decision, the chairman of Go8, and vice chancellor of the ANU, Ian...
Blackstone Invests $800 Million in Asian Oil-Based Energy Company
Jul 31, 2014  
Blackstone Energy Partners announced to invest $800 million in an Asian based energy company that is led by former industry executives.  Blackstone is popularly considered a part of the world’s largest administrator of alternatives to financial stocks and bonds. New York-based managing director, Angelo Acconcia of Blackstone Energy Partners said in an interview that Tamarind...
Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...